Research programme: respiratory disorder therapeutics - AzarGen Biotechnologies

Drug Profile

Research programme: respiratory disorder therapeutics - AzarGen Biotechnologies

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AzarGen Biotechnologies
  • Class Plant proteins; Pulmonary surfactant associated proteins
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neonatal respiratory distress syndrome

Most Recent Events

  • 25 Jul 2017 AzarGen Biotechnologies has patent protection for method of production of human pulmonary surfactant protein-B in Europe
  • 29 Sep 2016 AzarGen Biotechnologies and iBio Inc. enter into a commercial developemnt agreement for surfactant proteins for Neonatal respiratory distress syndrome before September 2016
  • 29 Sep 2016 Early research in Neonatal respiratory distress syndrome in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top